

Key Principles of Human Genetics and their application to Cardiovascular Disease (CVD)

Elizabeth S. Jordan, MMSc, CGC
Assistant Professor and Certified Genetic Counselor
Department of Internal Medicine - Division of Human Genetics
The Ohio State University
elizabeth.jordan@osumc.edu



AMERICAN
COLLEGE of
CARDIOLOGY®

Advancing Heart Care Worldwide

Disclosures


- Nothing to disclose.


Outline

- 1) Define the most common mode of inheritance observed in genetic CVD
- 2) Outline current variant classification nomenclature
- 3) Explore how reduced penetrance, variable expression, gene-environment interactions, and genetic/phenotypic heterogeneity complicates clinical presentation
- 4) Describe the diagnostic yield gap with current CVD genetic testing

Most genetic CV disease is inherited in an autosomal dominant pattern.

- Disease inherited in an **autosomal dominant** pattern requires only one abnormal copy in a gene pair for disease to occur
 - 50% risk to first degree relatives (parents, siblings, children) to also share abnormal copy of gene
- Autosomal recessive and X-linked inheritance also reported, particularly in pediatric cases, but are less commonly observed in adult onset CVD





How do you determine what variants are clinically relevant for diagnosis and risk prediction in family members?

Pathogenic and Likely Pathogenic variants are clinically significant

American College of Medical Genetics (ACMG)-classified P/LP variants are considered monogenic (single gene) causes of disease.

Pathogenic

Disease-causing variant

Likely Pathogenic

>95% confidence disease-causing

Variant of Uncertain Significance

Unknown if disease-causing or not


Likely Benign

>95% confidence NOT disease-causing

Benign

Not disease-causing





Official journal of the American College of Medical Genetics and Genomics

Open

SPECIAL ARTICLE

Genetics
inMedicine

Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen's Inherited Cardiomyopathy Working Group

Melissa A. Kelly, MS¹, Colleen Caleshu, MS², Steven M. Harrison, PhD¹, Stuart Cook, EdD³, Eden Haverfield, PhD⁵, Jan D.H. Jongbloed, MD⁶, Kate Orland, MS⁹, Gabriele Richard, MD⁷, Kate Thomson, BSc^{12,13}, Lisa M. Vincent, PhD⁸, Nicola Whiffin, PhD^{4,14}, Jodie Ingles, PhD¹⁰, Christopher Semsarian, MBBS PhD¹⁵, Jami L. Birgit Funke, PhD^{1,17,18}, for the ClinGen

Guidelines for the interpretation of sequence variant status: consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

Elizabeth C. Berglund, PhD^{1,2,16}, Sherri Bale, PhD³, David Bick, MD⁴, Soma Das, PhD⁵, David H. Ledbetter, PhD⁶, Wayne W. Grody, MD, PhD^{9,10,11}, Madhuri Hegde, PhD¹², Richard A. Kittles, PhD¹⁴, Karl Voelkerding, MD¹³ and Heidi L. Rehm, PhD¹⁵;

Circulation: Genomic and Precision Medicine

ORIGINAL ARTICLE

Variant Interpretation for Dilated Cardiomyopathy

Refinement of the American College of Medical Genetics and Genomics/ ClinGen Guidelines for the DCM Precision Medicine Study

Ana Morales, MS; Daniel D. Kinnamond, PhD; Elizabeth Jordan, MS; Julia Platt, MS; Matteo Vatta, PhD; Michael O. Dorschner, PhD; Carl A. Starkey, PhD; Jonathan O. Mead, BS; Tomohiko Ai, MD, PhD; Wylie Burke, MD, PhD; Julie Gastier-Foster, PhD; Gail P. Jarvik, MD, PhD; Heidi L. Rehm, PhD; Deborah A. Nickerson, PhD; Ray E. Hershberger, MD; on behalf of the DCM Precision Medicine study of the DCM Consortium*



Clinical Cardiovascular Genetic Counselors Take a Leading Role in Team-based Variant Classification

Chloe Reuter¹ • Megan E. Grove^{2,3} • Kate Orland⁴ •
Katherine Spoonamore⁵ • Colleen Caleshu^{1,2}




Fig. 2 Variant classification is team-based. 25/31 (81%) of genetic counselors who classify variants do so in a team-based fashion either with a cardiologist (12/31 (39.0%)), a geneticist (7/31 (23.0%)), or both (6/31 (17.0%)). 6/31 (19.0%) are the only provider involved in variant classification and all of those participants work with a cardiologist specialized in inherited disease. GC = genetic counselor

The clinical presentation of a genetic CVD can be complicated

Penetrance

- The percentage of people with

Expressivity

- The severity of a phenotype

This presents a challenge the clinician.

When genotype positive individuals have only absent, sub-clinical, or mild phenotypes, they may appear or be reported as “healthy” which can confuse or complicate the genetic risk assessment.


“incomplete” penetrance

The clinical presentation of a genetic CVD can be complicated

- Environment can modify penetrance and expression resulting from unique **gene-environment (GxE) interactions** among individuals, even within the same family.
- Such as:
 - Cardiotoxicity, alcoholism, and pregnancy in genetic DCM
 - Smoking, diabetes, and other conventional coronary artery disease risk factors in individuals with FH
 - Exercise in people with genetic predisposition to ACM/ARVC
 - Others...


The clinical presentation of a genetic CVD can be complicated

Marked genetic and phenotypic heterogeneity has also been described.



Hershberger et al. Nature Reviews (2013)

COLLEGE OF CARDIOLOGY



Jordan et al. Circulation May 2021

Sensitivity of genetic testing is not 100%.

Cardiomyopathy

Channelopathy

Familial
Hypercholesterolemia

Aortopathy

***A negative result does not exclude genetic cause.
Family members could still be at risk!***

Genes yet to be identified, regions of the genome that are not currently analyzed or well understood, complex multiple or common variant mechanisms, etc. may in part hold the remaining unsolved genetic background of CVD.

Key Takeaways

- 1) A majority of genetic CVD is due to pathogenic or likely pathogenic variants inherited in an autosomal dominant pattern
- 2) Reduced penetrance, variable expression, genetic/phenotypic heterogeneity, and GxE interactions can complicate clinical presentation of a patient/family
- 3) The complete genetic background of CVD remains unsolved, leaving family members still at risk

Thank you

Elizabeth S. Jordan, MMSc, CGC
Assistant Professor and Certified Genetic Counselor
Department of Internal Medicine - Division of Human Genetics
The Ohio State University
Elizabeth.Jordan@osumc.edu
[@eksjordan](https://twitter.com/eksjordan)



Advancing Heart Care Worldwide



**AMERICAN
COLLEGE of
CARDIOLOGY®**

Advancing Heart Care Worldwide